CSF1R and cutaneous melanoma: However, both our approach and the p-value strategy prioritized the “transmembrane receptor protein tyrosine kinase signaling pathway.” This finding is consistent with other studies that report certain RTKs such as PDGFRB and CSF1R drive intrinsic drug resistance to BRAFi in BRAFV600 cutaneous melanoma [29, 30].